智通财经APP获悉，金斯瑞生物科技(01548)盘中涨超10%，截至发稿，涨7.86%，报11.8港元，成交额5.28亿港元。
消息面上，金斯瑞已确认此前与高瓴资本达成的3亿股A类优先股交易已正式完成交割，交易对价为2.251亿美元（约17亿港元），交易后金斯瑞对蓬勃生物的持股比例增至85.09%。此外，工业和信息化部近日公示首批国家级重点培育中试平台名单，金斯瑞生命科学制剂中试平台和蓬勃生物一站式生物药中试平台成功入选。
公开资料显示，蓬勃生物是金斯瑞下属主营CDMO业务的公司。金斯瑞蓬勃生物拥有一站式生物药研发生产平台，致力于为基因和细胞治疗药物、疫苗及生物药发现、抗体蛋白药物等提供从靶点开发到商业化生产的端到端CDMO服务。此次收购将强化金斯瑞在CDMO领域的技术积累和市场竞争力，并有望通过Probio Cayman与礼新医药的合作（如PD-1/VEGF双抗项目）进一步拓展收入来源。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.